Literature DB >> 18600417

Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.

Akie Takano1, Noboru Oriuchi, Yoshito Tsushima, Ayako Taketomi-Takahashi, Takahito Nakajima, Yukiko Arisaka, Tetsuya Higuchi, Makoto Amanuma, Keigo Endo.   

Abstract

OBJECTIVE: To investigate the diagnostic features of whole-body diffusion-weighted magnetic resonance imaging (DWI) as compared with 2-[(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) and (123)I-meta-iodo-benzyl guanidine scintigraphy (MIBG) on metastatic lesions of patients with malignant pheochromocytoma or paraganglioma.
METHODS: We prospectively studied 11 patients with histologically confirmed pheochromocytoma/paraganglioma and possible metastatic lesions. FDG-PET, MIBG, and DWI examinations were performed within 1 week, and the images were visually interpreted. Abnormal positive uptake either on MIBG or on FDG-PET was considered as metastases. Abnormal high signal intensities on DWI were considered as metastases using conventional T1-and T2-weighted images as reference.
RESULTS: FDG-PET and DWI demonstrated metastatic lesions in all 11 patients, but MIBG showed no metastatic lesions in two patients. The numbers of lymph node metastases depicted on FDG-PET, MIBG, and DWI were 19, 6, and 39; bone metastases were 50, 49, and 60; liver metastases were 9, 9, and 15; lung metastases were 5, 7, and 5, respectively. MIBG failed to demonstrate many metastatic lesions, which were demonstrated on FDG-PET or DWI, although two mediastinal lymph node metastases, three lung metastases, and six bone metastases, which were not seen on DWI, were clearly demonstrated on MIBG. DWI showed 15 liver metastases, but 6 of them were not seen on FDG-PET or MIBG.
CONCLUSIONS: DWI may be particularly advantageous in depicting lymph node and liver metastases and may have a higher rate of detecting metastatic lesions when compared with MIBG or FDG-PET. The limitations of DWI were possible false-positive finding, and probable lower detectability of mediastinal lymph node and lung metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18600417     DOI: 10.1007/s12149-008-0128-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  12 in total

1.  Images of pheochromocytoma in adrenal glands.

Authors:  Shaunagh McDermott; Colin J McCarthy; Michael A Blake
Journal:  Gland Surg       Date:  2015-08

2.  Contrast- and non-contrast-enhanced ultrasonography (US) findings of hepatic metastasis from malignant pheochromocytoma/paraganglioma.

Authors:  Sachiko Nakano; Yoshito Tsushima; Tetsuya Higuchi; Ayako Taketomi-Takahashi; Makoto Amanuma
Journal:  Jpn J Radiol       Date:  2012-01-24       Impact factor: 2.374

Review 3.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

Review 4.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

5.  Comparison of diagnostic and prognostic capabilities of ¹⁸F-FDG-PET/CT, ¹³¹I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer.

Authors:  Shigeki Nagamachi; Hideyuki Wakamatsu; Shogo Kiyohara; Ryuichi Nishii; Youichi Mizutani; Seigo Fujita; Shigemi Futami; Hideo Arita; Masaomi Kuroki; Hiroshi Nakada; Noriko Uchino; Shozo Tamura; Keiichi Kawai
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

Review 6.  Adrenal pheochromocytoma: is it all or the tip of the iceberg?

Authors:  Ke Wang; Guanglei Tang; Yang Peng; Chang Li; Wenhao Fu; Ruixi Li; Jian Guan
Journal:  Jpn J Radiol       Date:  2021-09-21       Impact factor: 2.374

7.  Role of (18)F-FDG PET/CT, (123)I-MIBG SPECT, and CT in Restaging Patients Affected by Malignant Pheochromocytoma.

Authors:  Antonio Cantalamessa; Federico Caobelli; Barbara Paghera; Antonio Caobelli; Francesca Vavassori
Journal:  Nucl Med Mol Imaging       Date:  2011-05-03

Review 8.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

9.  Molecular challenges of neuroendocrine tumors.

Authors:  Parthik Patel; Karina Galoian
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

10.  Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases.

Authors:  Rachel Jorge D Cossetti; Regis Otaviano França Bezerra; Brenda Gumz; Adriana Telles; Frederico P Costa
Journal:  World J Surg Oncol       Date:  2012-05-16       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.